These genetic biomarkers, which included ERBB1 (EGFR), ERBB2 (HER2), ERBB3 (HER3), PTEN, FGFR2 and MET, are six genes that are known targets for clinical or pre-clinical targeted therapies in GC. This evidence concerns the gene FGFR2 and gastric cancer.